Repare Therapeutics Inc

Repare Therapeutics — Technical Presentation (October 2023)

47 slides from Repare Therapeutics's technical presentation, Oct 13, 2023

  1. Slide 1: Lunresertib MYTHIC Clinical Trial Update

    Insight that enriches. Precision that empowers. Lunresertib MYTHIC Clinical Trial Update October 13, 2023 Exhibit 99.1

  2. Slide 2: Agenda

    Agenda Welcome & Introduction Lloyd M. Segal, President & CEO Lunresertib Preliminary MYTHIC Monotherapy & Combination Therapy Clinical Trial Results Timothy Yap, MBBS, PhD, FRCP, Principal Investigator, MYTHIC Trial Conclusions & Lunresertib Development Plan Maria Koehler, MD, PhD, Chief Medical Of

  3. Slide 3: Disclaimer

    Disclaimer Statements contained in this presentation regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Words such as "anticipates," "believes," "expects," "intends," “plans,” “poten

  4. Slide 4: Developing Next-Generation Precision Oncology Therapeutics

    Differentiated and expanding clinical-stage pipeline Lunresertib: First-in-class oral PKMYT1 inhibitor (Phase 1/2) Camonsertib: ATR inhibitor (Partnered with Roche) Additional near-term clinical programs Potential across multiple tumor types Proprietary CRISPR-enabled SNIPRx platform Focused on geno

  5. Slide 5: Lunresertib: First-in-class, oral, small molecule, PKMYT1 inhibitor

    Lunresertib: First-in-class, oral, small molecule, PKMYT1 inhibitor Combination therapy achieved strong anti-tumor activity across multiple tumor types and tested genotypes; 33% overall response at preliminary RP2D (N=18) 50% RECIST response observed in camonsertib combination in largest cohort (gyn

  6. Slide 6: ~90K patients across tumor types; ~65K among top tumors

    ~90K patients across tumor types; ~65K among top tumors CCNE1 amplification or inactivating mutations in FBXW7 and PPP2R1A Genetic alterations largely mutually exclusive Addressing unmet need in critical patient populations Top Tumors (New Advanced Cases, US+UK/EU4) Top Tumors (New Advanced Cases, U

  7. Slide 7: Lunresertib Preliminary Monotherapy & Combination Therapy Clinical Trial Results

    Lunresertib Preliminary Monotherapy & Combination Therapy Clinical Trial Results Timothy Yap, MBBS, PhD, FRCP, Principal Investigator, MYTHIC Trial

  8. Slide 8: Study principal investigator: Timothy Yap

    Study principal investigator: Timothy Yap, MBBS, PhD, FRCP Medical Oncologist and Physician-Scientist at the University of Texas, MD Anderson Cancer Center Professor, Department for Investigational Cancer Therapeutics (Phase 1 Program) ​ Vice President, Head of Clinical Development in the Therapeuti

  9. Slide 9: Speaker disclosures: Timothy Yap

    Speaker disclosures: Timothy Yap, MBBS, PhD, FRCP I have the following relevant financial relationships to disclose: Employee of: University of Texas MD Anderson Cancer Center, where I am Vice President, Head of Clinical Development in the Therapeutics Discovery Division, which has a commercial inte

  10. Slide 10: PKMYT1 identified as synthetic lethal partner to CCNE1 amplification

    PKMYT1 was identified as a strong synthetic lethal partner to CCNE1 amplification1 1Gallo et al. CCNE1 amplification is synthetic lethal with PKMYT1 kinase inhibition. Nature. 2022; 604 (7907): 749-756. SNIPRx SL hits are LoF mutations that are essential for fitness in CCNE1-O/E cells but not their

  11. Slide 11: Lunresertib: Potent and selective first-in-class PKMYT1 inhibitor

    Lunresertib: Potent and selective first-in-class PKMYT1 inhibitor Potency Enzyme potency (IC50, nM) 3 HCC1569 CDK1 T14 phosphorylation (IC50, nM) 20 HCC1569 cell viability (EC50, nM) 19 PKMYT1 selectivity over WEE1 (cell-based ) >100-fold ADME Properties CYP inh (3A4, 2D6, 2C9, 1A2, 2C19) all >30 µM

  12. Slide 12: Lunresertib monotherapy inhibits xenograft growth

    Lunresertib monotherapy inhibits xenograft growth across doses and schedules HCC1569 CCNE1 amplified Breast Cancer CDX model 5-on/2-off, 5 days on / 2 days off; BID, twice daily; Lunre, lunresertib.

  13. Slide 13: PKMYT1 and ATR inhibitors synergize to enhance anti-tumor activity

    PKMYT1 and ATR inhibitors synergize to enhance anti-tumor activity1 Lunresertib-sensitizing alterations engage ATR through replication stress Combination of ATR and PKMYT1 inhibition enhances CDK1 activation and premature mitosis 1ANE poster B057: Gallo et al. Preclinical development of PKMYT1 and A

  14. Slide 14: Lunresertib and camonsertib combination active in tumor models

    Lunresertib and camonsertib combination treatment is active in CCNE1 amplified or FBXW7 altered tumor models Combination treatment drives tumor regressions at sub-efficacious single-agent doses *Additional internal Repare data, not shown. Free drug exposure of 5-10 mg/kg dose in mouse (AUC or Cmin)

  15. Slide 15: MYTHIC: PKMYT1 inhibition for the treatment of cancers (N=126)

    MYTHIC: PKMYT1 inHIbition for the treatment of Cancers (N=126) Module 1: Single agent lunresertib Primary endpoints: Safety and tolerability RP2D, schedule Other endpoints: PK PD in paired tumor biopsies Preliminary antitumor activity Kinetics of ctDNA Module 1 initiated Apr 2021 Data snapshot Sept

  16. Slide 16: MYTHIC: Patient demographics

    MYTHIC: Patient demographics Parameter (Lun alone) N=67 (Lun + Cam) N= 59 Sex, n (%) Male Female 17 (25.4) 50 (74.6) 15 (25.4) 44 (74.6) Age (years) Median (range) ≥65 years, n (%) 60 (15, 81) 25 (37.3) 65 (16, 81) 30 (50.8) ECOG PSa, n (%) 0 1/2 21 (31.3) 44 (65.7) /1 (1.5) 23 (39.0) 35 (59.3) / 0

  17. Slide 17: Multiple doses/schedules of lunresertib tested

    Multiple doses/schedules of lunresertib tested Adaptive BOIN design, sufficient cohort sizes to establish MTD/RP2D QD dose tested first, once half-life known, BID dose was then tested Continuous and intermittent schedules showed similar activity in preclinical efficacy models DLT: reversible rash In

  18. Slide 18: Lunresertib monotherapy: Treatment related adverse events

    TRAEs in ≥15% of patients, n (%) All Grades G3 G4 All Grades G3 G4 Rash* 23 (34.3) 5 (7.5) 0 4 (50.0) 0 0 Nausea/Vomiting 21 (31.3) 1 (1.5) 0 2 (25.0) 0 0 Anemia 15 (22.4) 4 (6.0) 0 1 (12.5) 0 0 Fatigue 15 (22.4) 1 (1.5) 0 3 (37.5) 0 0 Lunresertib monotherapy: Treatment related adverse events (TRAEs

  19. Slide 19: Target PK exposures achieved with lunresertib

    Target PK exposures achieved with lunresertib Human lunresertib PK is linear up to daily doses of 160-240 mg with a half-life of ~9 hours PK exposures similar between QD and BID schedules and exceeded the target exposure for inhibition of pCDK1 BID, twice daily; Conc, concentration; pCDK1, phosphory

  20. Slide 20: Lunresertib monotherapy mechanism of action confirmed in paired biopsies

    Lunresertib monotherapy mechanism of action confirmed in paired biopsies pCDK1-Thr14 (Direct Target Inhibition IHC, pCDK1 target -50%*) ƔH2AX (Induction of DNA Damage IHC, ƔH2AX target 2-fold) ƔH2AX PKMYT1 CDK1 Lunre Thr14 DNA damage Pretreatment vs. On-treatment (n=17; p=0.003) Pretreatment vs. On-

  21. Slide 21: Anti-tumor activity with lunresertib monotherapy

    Anti-tumor activity with lunresertib monotherapy FBXW7 PPP2R1A Baseline Left external iliac chain LN TA #1 – Week 6 Overall response: cPR (RECIST) RECIST target lesion decrease -41% Received therapy for 8.3 months Female 73 years old Metastatic recurrent uterine carcinosarcoma & One RECIST responder

  22. Slide 22: MYTHIC: PKMYT1 inhibition for the treatment of cancers (N=126)

    MYTHIC: PKMYT1 inHIbition for the treatment of Cancers (N=126) Module 1: Single agent lunresertib Primary endpoints: Safety and tolerability RP2D, schedule Other endpoints: PK PD in paired tumor biopsies Preliminary antitumor activity Kinetics of ctDNA Module 1 initiated Apr 2021 Data snapshot Sept

  23. Slide 23: Lunresertib with camonsertib dose escalation

    Lunresertib with camonsertib dose escalation † Tested doses derived from single agent exposures values. * Of the 59 patients, 57 were given 80mg and 2 patients received 120mg of camonsertib. ** One patient started at the daily dose of lunresertib 80mg QD 3 d on/ 4d off and was later escalated to 80m

  24. Slide 24: Lunresertib + camonsertib: Treatment related adverse events

    Lunresertib + camonsertib: Treatment related adverse events (TRAEs) TRAEs in ≥15% of patients, n (%) All Grades G3 G4 All Grades G3 G4 Anemia 40 (67.8) 25 (42.4) 0 13 (65.0) 9 (45.0) 0 Nausea/Vomiting 38 (64.4) 0 0 9 (45.0) 0 0 Fatigue 24 (40.7) 0 0 5 (25.0) 0 0 Rash* 23 (39.0) 1 (1.7) 0 7 (35.0) 0

  25. Slide 25: Direct target inhibition enhanced with combination treatment

    Direct target inhibition (pCDK1-Thr14) is enhanced with combination treatment *Due to assay differences, IHC ~50% target inhibition corresponds to ~80% inhibition by ELISA when maximal tumor growth inhibition in preclinical models was recorded. ATR, ataxia telangiectasia and Rad-3 related; Cam, camo

  26. Slide 26: Responses to combination observed across tumor types and alterations

    Responses to combination observed across tumor types and lunresertib-sensitizing alterations * One response evaluable patient became uPR and four patients had responses confirmed after the Sept. 5, 2023 cutoff, data as of Oct. 6, 2023. Relevant patient tumor co-mutations †BRCA1 rearrangement and ‡BR

  27. Slide 27: Frequent and deep tumor reductions with combination

    *Efficacy evaluable patients only (≥1 post-baseline tumor assessment). Other tumor types include cervical (n=1), esophageal (n=1), GI (n=1), liver (n=1), lung (n=3), melanoma (n=1), osteosarcoma (n=1), pancreatic (n=2), and upper GI (n=1). CBR: overall response or time on treatment ≥ 16 wk w/o progr

  28. Slide 28: Tumor reductions in gynecologic cancers with combination treatment

    Most patients with gynecologic cancers had tumor reductions with combination treatment * Gynecologic cancers: ovarian, endometrial, and cervical cancers. Data represent the efficacy evaluable population (≥1 post-baseline tumor assessment). CBR, clinical benefit rate; OR, overall response based on RE

  29. Slide 29: Meaningful tumor reductions across lunresertib-sensitizing alterations

    Meaningful tumor reductions across lunresertib-sensitizing alterations # patients with lunresertib-sensitizing co-alterations: 1 each (FBXW7/CCNE1, PPP2R1A/CCNE1, and PPP2R1A/FBXW7). Data represent the efficacy evaluable patient population with ≥ 1 post-baseline tumor assessment. CBR, clinical benef

  30. Slide 30: Clinical benefit across alterations and doses

    Clinical benefit: Combination treatment across lunresertib-sensitizing alterations and doses OR across all genotypes: 33.3% in CCNE1 (n=18) 17.4% in FBXW7 (n=23) 21.4% in PPP2R1A (n=14) CBR is promising across genotypes: 44% in CCNE1 (n=18) 35% in FBXW7 (n=23) 50% in PPP2R1A (n=14) Treatment ongoing

  31. Slide 31: Significantly higher molecular responses with combination treatment

    Significantly higher molecular responses confirm the benefit of combination treatment Molecular responses were observed across lunresertib-sensitizing molecular alterations1 1ANE poster B057: Gallo et al. Molecular response: ≥ 50% decline in mVAF assessed by Tempus xF and Tempus xF+ gene panels for

  32. Slide 32: Early response in recurrent FBXW7 mutated colorectal adenocarcinoma

    Early response in recurrent FBXW7 mutated colorectal adenocarcinoma FBXW7 Male 63 years old Recurrent colorectal adenocarcinoma Mutation Lunre 240mg QD 3/4 Cam 80mg QD 3/4 Overall response: cPR (RECIST) RECIST target lesion decrease -43.3% Received therapy for 27.6 weeks Left para-aortic lymph node

  33. Slide 33: Gradual response heralded by CA-125 decrease; CCNE1 amplified ovarian cancer

    Gradual response heralded by CA-125 decrease; recurrent CCNE1 amplified ovarian cancer Overall response: cPR (RECIST) RECIST target lesion decrease -70.2% Therapy ongoing for >21 weeks Female 56 years old High grade serous ovarian carcinoma Amplification RP2D: Lunre 80mg BID 3/4 Cam 80mg QD 3/4 CCNE

  34. Slide 34: Prompt response in recurrent cervical carcinosarcoma

    Prompt response in recurrent cervical carcinosarcoma with a PPP2R1A mutation Female 66 years old Recurrent cervical carcinosarcoma Mutation RP2D: Lunre 80mg BID 3/4 Cam 80mg QD 3/4 T01 Lymph node external iliac left PPP2R1A Baseline 6 weeks 12 weeks Tumor assessment CA-125 dynamics Overall response:

  35. Slide 35: Conclusions & Lunresertib Development Plan

    Conclusions & Lunresertib Development Plan Maria Koehler, MD, PhD, Chief Medical Officer

  36. Slide 36: MYTHIC Preliminary Phase 1 Trial Results

    Lunresertib: MYTHIC Preliminary Phase 1 Trial Results (M1: Monotherapy) (M2: Camonsertib Combination Therapy) MONOTHERAPY Safe, well tolerated, and anti-tumor activity established (N=67) Recommended Phase 2 dose: 80 to 100mg twice daily in intermittent schedule CAMONSERTIB COMBINATION THERAPY Safe,

  37. Slide 37: Lunresertib + camonsertib combination therapy (additional data)

    Lunresertib + camonsertib combination therapy (additional data) MYTHIC is a dose finding Phase 1 study: Preliminary RP2D range identified, schedule optimization ongoing. RP2D is important; only 18 pts were treated at preliminary RP2D range. Anemia is the primary tolerability issue to alleviate. Our

  38. Slide 38: Gynecologic cancers show criticality of sufficient exposure

    Gynecologic cancers provide most robust example of criticality of sufficient exposure Treatment at preliminary RP2D increases efficacy Gynecologic Cancers Only: N (%) RP2D (N=10) Non-RP2D (N=16) Overall Response (RECIST/CA-125) 6 (60.0%) 4 (25.0%) RECIST response (confirmed+unconfirmed) ** 5 (50.0%)

  39. Slide 39: Anemia likely a result of synergistic combination effect

    Anemia likely a result of synergistic combination effect Mostly a sole, manageable event, suggestive of narrow bone marrow effect Dose optimization and individualized patient management now in place: Maintain RP2D weekly in patients without anemia Early onset: schedule adjustment Late onset: “on dem

  40. Slide 40: Tumor reductions in gynecologic cancers with combination treatment

    Most patients with gynecologic cancers had tumor reductions with combination treatment * Gynecologic cancers: ovarian, endometrial, and cervical cancers. Data represent the efficacy evaluable population (≥1 post-baseline tumor assessment). CBR, clinical benefit rate; OR, overall response based on RE

  41. Slide 41: Emerging signals in non-gynecologic tumors

    Small #pts in 11 different tumors 1/3 of patients with NSCLC have 10m PFS 1/3 of patients with upper GI cancer have 10m PFS 1/2 of patients with cholangio: cPR 1/3 of patients with breast cancer: uPR, continuous target lesion shrinkage Opportunity across multiple tumor types: emerging signals from P

  42. Slide 42: Evolving broad trial program: sponsored and collaborative

    Evolving broad trial program: sponsored and collaborative PPP2R1A FBXW7 Recurrent solid tumors Key inclusion criteria: CCNE1 amplification or inactivating mutations Determine RP2D dose / schedule Progress to late-stage trials MAGNETIC: + Gemcitabine MYTHIC: + Camonsertib MINOTAUR: + FOLFIRI IST: + C

  43. Slide 43: MYTHIC trial: Key takeaways and next steps

    Oncology and patient communities taking high interest in emerging data accelerating the expansion of lunresertib development as MYTHIC moves ahead MYTHIC trial: Key takeaways and next steps Validated lunresertib mechanism of action and SNIPRx preclinical patient selection approach Safety, tolerabili

  44. Slide 44: Upcoming Catalysts

    Upcoming Catalysts Lloyd M. Segal, President & CEO

  45. Slide 45: Upcoming milestones

    Upcoming milestones 2H 2024 2H 2023 1H 2024 Camonsertib Phase 2 TAPISTRY trial initiation Lunresertib + carboplatin/paclitaxel combination Phase 1 IST initiation RP-1664 and RP-3467 (Polθi) focused investor event RP-1664 clinical trial initiation Initial lunresertib + FOLFIRI combination Phase 1 dat

  46. Slide 46: Q&A

    Q&A Lloyd M. Segal President & CEO Timothy Yap, MBBS, PhD, FRCP Principal Investigator, MYTHIC Trial Maria Koehler, MD, PhD Chief Medical Officer Steve Forte, CPA Chief Financial Officer Mike Zinda, PhD Chief Scientific Officer

  47. Slide 47: Lunresertib MYTHIC Clinical Trial Update

    Insight that enriches. Precision that empowers. Lunresertib MYTHIC Clinical Trial Update October 13, 2023

Repare Therapeutics — Technical Presentation (October 2023) on 6ix